Transparency Guidelines
Guidelines on Transparency of Relationship between Corporate Activities and Medical Institutions
Apr1,2013
RIKEN GENESIS CO., LTD.
Riken Genesis Co., Ltd. (hereinafter "we") aims to contribute to the practical application and improvement of personalized medicine care for citizens and patients through the provide of in vitro diagnostic reagents and research reagents by conducting basic medical and pharmaceutical research and genetic analysis research in cooperation with universities and research institutes and medical institutions.
In conducting these activities, in accordance with the "Guidelines for Transparency of Corporate Activities and Medical Institutions" (*1) issued by the Japan Association of Clinical Tests, the government will disclose information on collaborative activities with medical institutions, etc. with the purpose of increasing the transparency of the relationship between the wee and research institutes and medical institutions such as universities, etc. and becoming a company that is confidence by a wide range of stakeholders.
1. Timing and Methods of Publication
Information on funding for medical institutions in each fiscal year (*2) will be made available on the Web site after settlement of accounts for the fiscal year.
Disclosure will start in fiscal 2014 (disclosed to the public for fiscal 2013).
2. Scope and Content of Publication
The scope and content of information on funding for medical institutions, etc. disclosed by the Web is as follows.
A: R&D expenses
R&D expenses include expenses for clinical performance tests and performance evaluations, adverse reaction reports conducted under public regulations such as the GVP ordinance, and various manufacture-marketing surveys.
- Joint Research Expenses (Annual Total)
- Commissioned research expenses (total amount per year)
B: Grant-in-Aid for Academic Research
Scholarship grants and general donations for the purpose of promoting academic research and research grants, as well as conference donations and conference co-sponsoring expenses to support academic societies
- Scholarship Donations (○○University ○○Classes: ○○cases, ○○○en)
- General donations (○○○ University or ○○○ Foundation: ○○yen)
- Donations from academic societies (Circle ○○○ Society: ○○)
- Costs co-sponsored by the academic society (○○○ Seminar at the Society of ○○: ○○ yen)
C: Draft writing fees, etc.
Consideration for lectures, writing of manuscripts, and requests for consulting services to provide medical and pharmaceutical information
- Lecturer fee (○○○ Professor, Department Director, Department of ○○ at ○○○ University or ○○○ Hospital: ○○cases, ○○○en)
- Letter for writing or reviewing the manuscript (○○○ Professor, Department Director, Department of ○○○○ at ○○○ University or Hospital : ○○cases, ○○○en)
- Outsourcing expenses for consulting, etc.(Professor or Director, Department of ○○○ at ○○○ University or Hospital: ○○cases, ○○○en)
D: Costs related to the provide of information
Expenses for lectures and briefings to provide medical and pharmaceutical information to medical professionals
- Lecture fee (annual number and total amount)
- Expenses for explanatory meetings (Annual number and total amount)
- Expenses for explanatory meetings (Annual number and total amount)
E: Other expenses
Costs for social rituals such as treatment
- Expenses for compensation, etc. (Annual total)
(*1) Guidelines for Transparency of Corporate Activities and Medical Institutions, Transparency Guidelines Q & A, and In Vitro Diagnostic Drugs Promotion Guidelines by the Japan Clinical Tests Association
(*2) "Year" means the period from April 1 of the current year to the end of March of the following year.